Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer
Authors:
- John SarantopoulosJSJohn Sarantopoulos
- Monica M. MitaMMMonica M. Mita
- Michael J. BirrerMBMichael J. Birrer
- Lee D. CranmerLCLee D. Cranmer
- Luis T. CamposLCLuis T. Campos
- Xiaoping ZhangXZXiaoping Zhang
- Penelope BristowPBPenelope Bristow
- Hidekuni KaitoHKHidekuni Kaito
- Vincent StroutVSVincent Strout
- Luis H. CamachoLCLuis H. Camacho
- 27 October 2015
- journal article
- Published by Springer Nature in Targeted Oncology
- Vol. 11 (3) , 317-327
Abstract
KHK2866 is a recombinant, humanized, non-fucosylated, monoclonal antibody directed at heparin-binding epidermal growth factor-like growth factor (HB-EGF). To determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, potential immunogenicity, and preliminary clinical efficacy of KHK2866 monotherapy in patients with advanced and refractory cancer in a first-in-human, phase 1 study. Using a standard 3 + 3 dose-escalation design, 20 patients received KHK2866 (0.3, 1, and 3 mg/kg) intravenously once weekly. Two additional patients received 0.1 mg/kg in a cohort which was subsequently added following protocol amendment. The first three patients enrolled experienced grade 2 hypersensitivity (acute infusion reactions) after the first dose of KHK2866. After prophylactic treatment with an H1-blocker and corticosteroids in subsequently recruited patients, two grade 2 hypersensitivity reactions were observed in the remaining 19 patients. Grade 2/3 neurotoxicity appeared to be dose-limiting at 3 mg/kg in the original dose-escalation cohorts (n = 2), at 1 mg/kg in the MTD dose expansion cohort (n = 1), and at 0.1 mg/kg (n = 1). Neurotoxicity was manifested as complex partial seizure activity, aphasia, and confusion after first-dose administration. Pharmacokinetic exposure to KHK2866 increased proportionally to dose. Mean elimination half-life was 71.9–118 h over the dose range from 0.3 to 3 mg/kg. All KHK2866 doses decreased serum free HB-EGF levels, generally below the lower limit of quantification. The study was terminated because of neuropsychiatric toxicity. The only predictive factor for neuropsychiatric toxicity was administration of KHK2866. These effects were reversible, but were not predictable. Their etiology is not presently understood. [Study registered at ClinicalTrials.gov #NCT0179291]Keywords
Funding Information
- Kyowa Hakko Kirin, Inc
- Cancer Center Support Grant (P30CA054174)
This publication has 43 references indexed in Scilit:
- Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cellsOncogene, 2010
- Generation and Characterization of Conditional Heparin-Binding EGF-Like Growth Factor Knockout MicePLOS ONE, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206Journal of Clinical Oncology, 2008
- Membrane‐anchored growth factors, the epidermal growth factor family: Beyond receptor ligandsCancer Science, 2008
- Validation of HB-EGF and amphiregulin as targets for human cancer therapyBiochemical and Biophysical Research Communications, 2008
- Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistanceOncogene, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Regional distribution of heparin-binding epidermal growth factor-like growth factor mRNA and protein in adult rat forebrainNeuroscience Letters, 1996
- Increased expression of integrins by heparin-binding EGF like growth factor in human esophageal cancer cellsCancer Letters, 1996